Does the media prefer IRWD or ABBV?

In the previous week, AbbVie had 74 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 77 mentions for AbbVie and 3 mentions for Ironwood Pharmaceuticals. AbbVie's average media sentiment score of 1.24 beat Ironwood Pharmaceuticals' score of 0.94 indicating that AbbVie is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ironwood Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive AbbVie 57 Very Positive mention(s) 8 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer IRWD or NRIX?

In the previous week, Ironwood Pharmaceuticals had 1 more articles in the media than Nurix Therapeutics. MarketBeat recorded 3 mentions for Ironwood Pharmaceuticals and 2 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 1.32 beat Ironwood Pharmaceuticals' score of 0.94 indicating that Nurix Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ironwood Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Nurix Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor BEAM or IRWD?

In the previous week, Beam Therapeutics had 25 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 28 mentions for Beam Therapeutics and 3 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.94 beat Beam Therapeutics' score of 0.48 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 6 Very Positive mention(s) 4 Positive mention(s) 15 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ironwood Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IRWD or PHVS?

In the previous week, Pharvaris had 41 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 44 mentions for Pharvaris and 3 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.94 beat Pharvaris' score of 0.52 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ironwood Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Pharvaris 14 Very Positive mention(s) 7 Positive mention(s) 15 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to VRDN or IRWD?

In the previous week, Viridian Therapeutics had 2 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 5 mentions for Viridian Therapeutics and 3 mentions for Ironwood Pharmaceuticals. Viridian Therapeutics' average media sentiment score of 1.07 beat Ironwood Pharmaceuticals' score of 0.94 indicating that Viridian Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viridian Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ironwood Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Ironwood Pharmaceuticals (IRWD) Competitors

$4.17 +0.09 (+2.21%)

Closing price 09/14/2026 04:00 PM Eastern

Extended Trading

$4.14 -0.04 (-0.84%)

As of 09/14/2026 07:30 PM Eastern

Compare

IRWD vs. ABBV, NRIX, BEAM, PHVS, and VRDN

Should you buy Ironwood Pharmaceuticals stock or one of its competitors? Ironwood Pharmaceuticals's main competitors and comparable companies include AbbVie (ABBV), Nurix Therapeutics (NRIX), Beam Therapeutics (BEAM), Pharvaris (PHVS), and Viridian Therapeutics (VRDN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Ironwood Pharmaceuticals compare to AbbVie?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and AbbVie (NYSE:ABBV) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

Ironwood Pharmaceuticals presently has a consensus target price of $6.23, indicating a potential upside of 49.48%. AbbVie has a consensus target price of $276.64, indicating a potential upside of 5.72%. Given Ironwood Pharmaceuticals' higher probable upside, equities research analysts clearly believe Ironwood Pharmaceuticals is more favorable than AbbVie.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ironwood Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57
AbbVie	0 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	2 Strong Buy rating(s)	2.88

70.2% of AbbVie shares are held by institutional investors. 9.3% of Ironwood Pharmaceuticals shares are held by insiders. Comparatively, 0.1% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Ironwood Pharmaceuticals has a beta of 0.2, indicating that its share price is 80% less volatile than the broader market. Comparatively, AbbVie has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

Ironwood Pharmaceuticals has a net margin of 33.36% compared to AbbVie's net margin of 9.80%. Ironwood Pharmaceuticals' return on equity of -58.38% beat AbbVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ironwood Pharmaceuticals	33.36%	-58.38%	34.93%
AbbVie	9.80%	-422.07%	14.34%

AbbVie has higher revenue and earnings than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ironwood Pharmaceuticals	$296.15M	2.33	$24.02M	$0.77	5.42
AbbVie	$61.16B	7.56	$4.23B	$3.54	73.92

In the previous week, AbbVie had 74 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 77 mentions for AbbVie and 3 mentions for Ironwood Pharmaceuticals. AbbVie's average media sentiment score of 1.24 beat Ironwood Pharmaceuticals' score of 0.94 indicating that AbbVie is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ironwood Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
AbbVie	57 Very Positive mention(s)	8 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

AbbVie beats Ironwood Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Ironwood Pharmaceuticals compare to Nurix Therapeutics?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and Nurix Therapeutics (NASDAQ:NRIX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, media sentiment, profitability, dividends, earnings and analyst recommendations.

In the previous week, Ironwood Pharmaceuticals had 1 more articles in the media than Nurix Therapeutics. MarketBeat recorded 3 mentions for Ironwood Pharmaceuticals and 2 mentions for Nurix Therapeutics. Nurix Therapeutics' average media sentiment score of 1.32 beat Ironwood Pharmaceuticals' score of 0.94 indicating that Nurix Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ironwood Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Nurix Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ironwood Pharmaceuticals has higher revenue and earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ironwood Pharmaceuticals	$296.15M	2.33	$24.02M	$0.77	5.42
Nurix Therapeutics	$36.77M	72.04	-$264.46M	-$3.45	N/A

Ironwood Pharmaceuticals has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.8, indicating that its stock price is 80% more volatile than the broader market.

Ironwood Pharmaceuticals currently has a consensus target price of $6.23, suggesting a potential upside of 49.48%. Nurix Therapeutics has a consensus target price of $34.21, suggesting a potential upside of 34.07%. Given Ironwood Pharmaceuticals' higher possible upside, equities analysts plainly believe Ironwood Pharmaceuticals is more favorable than Nurix Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ironwood Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57
Nurix Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Ironwood Pharmaceuticals has a net margin of 33.36% compared to Nurix Therapeutics' net margin of -928.44%. Ironwood Pharmaceuticals' return on equity of -58.38% beat Nurix Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ironwood Pharmaceuticals	33.36%	-58.38%	34.93%
Nurix Therapeutics	-928.44%	-76.09%	-57.31%

Summary

Ironwood Pharmaceuticals beats Nurix Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Ironwood Pharmaceuticals compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations.

Ironwood Pharmaceuticals has higher revenue and earnings than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$156.04M	15.97	-$79.99M	-$0.86	N/A
Ironwood Pharmaceuticals	$296.15M	2.33	$24.02M	$0.77	5.42

Beam Therapeutics presently has a consensus target price of $49.00, indicating a potential upside of 103.15%. Ironwood Pharmaceuticals has a consensus target price of $6.23, indicating a potential upside of 49.48%. Given Beam Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Beam Therapeutics is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Ironwood Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57

Ironwood Pharmaceuticals has a net margin of 33.36% compared to Beam Therapeutics' net margin of -54.75%. Beam Therapeutics' return on equity of -30.71% beat Ironwood Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-54.75%	-30.71%	-24.07%
Ironwood Pharmaceuticals	33.36%	-58.38%	34.93%

99.7% of Beam Therapeutics shares are owned by institutional investors. 3.8% of Beam Therapeutics shares are owned by company insiders. Comparatively, 9.3% of Ironwood Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Beam Therapeutics had 25 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 28 mentions for Beam Therapeutics and 3 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.94 beat Beam Therapeutics' score of 0.48 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	6 Very Positive mention(s)	4 Positive mention(s)	15 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ironwood Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Beam Therapeutics has a beta of 2.22, suggesting that its share price is 122% more volatile than the broader market. Comparatively, Ironwood Pharmaceuticals has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market.

Summary

Ironwood Pharmaceuticals beats Beam Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Ironwood Pharmaceuticals compare to Pharvaris?

Ironwood Pharmaceuticals (NASDAQ:IRWD) and Pharvaris (NASDAQ:PHVS) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, media sentiment, dividends, analyst recommendations, valuation, risk and profitability.

Ironwood Pharmaceuticals has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market. Comparatively, Pharvaris has a beta of -2.33, indicating that its stock price is 333% less volatile than the broader market.

Ironwood Pharmaceuticals has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ironwood Pharmaceuticals	$296.15M	2.33	$24.02M	$0.77	5.42
Pharvaris	N/A	N/A	-$198.79M	-$3.05	N/A

Ironwood Pharmaceuticals has a net margin of 33.36% compared to Pharvaris' net margin of 0.00%. Ironwood Pharmaceuticals' return on equity of -58.38% beat Pharvaris' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ironwood Pharmaceuticals	33.36%	-58.38%	34.93%
Pharvaris	N/A	-61.40%	-56.00%

In the previous week, Pharvaris had 41 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 44 mentions for Pharvaris and 3 mentions for Ironwood Pharmaceuticals. Ironwood Pharmaceuticals' average media sentiment score of 0.94 beat Pharvaris' score of 0.52 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ironwood Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharvaris	14 Very Positive mention(s)	7 Positive mention(s)	15 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ironwood Pharmaceuticals currently has a consensus target price of $6.23, suggesting a potential upside of 49.48%. Pharvaris has a consensus target price of $59.87, suggesting a potential upside of 54.06%. Given Pharvaris' stronger consensus rating and higher probable upside, analysts plainly believe Pharvaris is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ironwood Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57
Pharvaris	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Ironwood Pharmaceuticals beats Pharvaris on 10 of the 14 factors compared between the two stocks.

How does Ironwood Pharmaceuticals compare to Viridian Therapeutics?

Viridian Therapeutics (NASDAQ:VRDN) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, institutional ownership, valuation, earnings, risk, profitability and dividends.

Viridian Therapeutics currently has a consensus price target of $38.54, indicating a potential upside of 73.60%. Ironwood Pharmaceuticals has a consensus price target of $6.23, indicating a potential upside of 49.48%. Given Viridian Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Viridian Therapeutics is more favorable than Ironwood Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viridian Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.85
Ironwood Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.57

In the previous week, Viridian Therapeutics had 2 more articles in the media than Ironwood Pharmaceuticals. MarketBeat recorded 5 mentions for Viridian Therapeutics and 3 mentions for Ironwood Pharmaceuticals. Viridian Therapeutics' average media sentiment score of 1.07 beat Ironwood Pharmaceuticals' score of 0.94 indicating that Viridian Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Viridian Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ironwood Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Ironwood Pharmaceuticals has a net margin of 33.36% compared to Viridian Therapeutics' net margin of -505.86%. Ironwood Pharmaceuticals' return on equity of -58.38% beat Viridian Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Viridian Therapeutics	-505.86%	-72.97%	-42.80%
Ironwood Pharmaceuticals	33.36%	-58.38%	34.93%

Viridian Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market. Comparatively, Ironwood Pharmaceuticals has a beta of 0.2, indicating that its stock price is 80% less volatile than the broader market.

Ironwood Pharmaceuticals has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Ironwood Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viridian Therapeutics	$71.13M	35.36	-$342.60M	-$3.37	N/A
Ironwood Pharmaceuticals	$296.15M	2.33	$24.02M	$0.77	5.42

Summary

Ironwood Pharmaceuticals beats Viridian Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Ironwood Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IRWD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IRWD vs. The Competition

Export

Metric	Ironwood Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$674.18M	$3.86B	$7.15B	$13.98B
Dividend Yield	N/A	3.66%	2.57%	11.71%
P/E Ratio	5.42	14.33	273.28	25.37
Price / Sales	2.33	1,346.89	615.54	75.36
Price / Cash	15.85	43.64	28.42	34.96
Price / Book	-2.59	15.26	10.43	6.24
Net Income	$24.02M	-$22.78M	$3.49B	$358.08M
7 Day Performance	N/A	-0.79%	-1.15%	-0.70%
1 Month Performance	-3.25%	2.12%	0.56%	-2.76%
1 Year Performance	225.78%	41.90%	20.17%	6.72%

Ironwood Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IRWD Ironwood Pharmaceuticals	2.543 of 5 stars	$4.17 +2.2%	$6.23 +49.5%	+218.3%	$674.18M	$296.15M	5.42	100
ABBV AbbVie	3.9927 of 5 stars	$251.38 -2.0%	$275.95 +9.8%	+19.8%	$444.52B	$61.16B	71.07	57,000	Positive News Dividend Announcement
NRIX Nurix Therapeutics	3.0532 of 5 stars	$25.99 -0.6%	$34.21 +31.6%	+182.3%	$2.71B	$83.98M	N/A	300	Gap Down
BEAM Beam Therapeutics	2.3538 of 5 stars	$25.83 -12.9%	$49.00 +89.7%	+17.1%	$2.65B	$139.74M	N/A	510	Analyst Downgrade
PHVS Pharvaris	3.5896 of 5 stars	$41.16 +16.8%	$51.08 +24.1%	+67.5%	$2.63B	N/A	N/A	30	Analyst Forecast Insider Trade High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IRWD) was last updated on 9/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ironwood Pharmaceuticals (IRWD) Competitors

IRWD vs. ABBV, NRIX, BEAM, PHVS, and VRDN

How does Ironwood Pharmaceuticals compare to AbbVie?

Summary

How does Ironwood Pharmaceuticals compare to Nurix Therapeutics?

Summary

How does Ironwood Pharmaceuticals compare to Beam Therapeutics?

Summary

How does Ironwood Pharmaceuticals compare to Pharvaris?

Summary

How does Ironwood Pharmaceuticals compare to Viridian Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRWD vs. The Competition

Ironwood Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ironwood Pharmaceuticals (IRWD) Competitors

IRWD vs. ABBV, NRIX, BEAM, PHVS, and VRDN

How does Ironwood Pharmaceuticals compare to AbbVie?

Do analysts rate IRWD or ABBV?

Do institutionals & insiders hold more shares of IRWD or ABBV?

Which has more volatility & risk, IRWD or ABBV?

Is IRWD or ABBV more profitable?

Which has stronger earnings & valuation, IRWD or ABBV?

Does the media prefer IRWD or ABBV?

Summary

How does Ironwood Pharmaceuticals compare to Nurix Therapeutics?

Does the media prefer IRWD or NRIX?

Which has better valuation & earnings, IRWD or NRIX?

Which has more volatility & risk, IRWD or NRIX?

Do analysts rate IRWD or NRIX?

Is IRWD or NRIX more profitable?

Summary

How does Ironwood Pharmaceuticals compare to Beam Therapeutics?

Which has better earnings & valuation, BEAM or IRWD?

Do analysts rate BEAM or IRWD?

Is BEAM or IRWD more profitable?

Do institutionals and insiders hold more shares of BEAM or IRWD?

Does the media favor BEAM or IRWD?

Which has more risk and volatility, BEAM or IRWD?

Summary

How does Ironwood Pharmaceuticals compare to Pharvaris?

Which has more volatility and risk, IRWD or PHVS?

Which has stronger earnings & valuation, IRWD or PHVS?

Is IRWD or PHVS more profitable?

Does the media favor IRWD or PHVS?

Do analysts prefer IRWD or PHVS?

Summary

How does Ironwood Pharmaceuticals compare to Viridian Therapeutics?

Do analysts recommend VRDN or IRWD?

Does the media refer more to VRDN or IRWD?

Is VRDN or IRWD more profitable?

Which has more volatility and risk, VRDN or IRWD?

Which has stronger valuation and earnings, VRDN or IRWD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IRWD vs. The Competition

Ironwood Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools